Get the Stockscreener App
2.08
1.89%
-0.04
Pre-market:
2.08
Inmune Bio Inc stock is traded at $2.08, with a volume of 436.03K.
It is down -1.89% in the last 24 hours and up +7.22% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$2.12
Open:
$2.06
24h Volume:
436.03K
Relative Volume:
0.58
Market Cap:
$55.30M
Revenue:
$50,000
Net Income/Loss:
$-41.60M
P/E Ratio:
-1.2274
EPS:
-1.6946
Net Cash Flow:
$-20.20M
1W Performance:
+8.90%
1M Performance:
+7.22%
6M Performance:
+32.48%
1Y Performance:
-13.33%
1-Day Range:
$2.01
$2.12
1-Week Range:
$1.79
$2.195
52-Week Range:
$1.09
$2.6091
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.08 | 45.99M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
529.65 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.00 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
864.74 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.55 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - aol.com
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
INmune Bio Q2 Earnings Call Highlights - sharewise.com
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inmune Bio, Inc. Q2 2026: Revenue $0 Net loss $(1.27)M, EPS $(0.05) — 10-Q Summary - TradingView
INmune Bio (NASDAQ: INMB) posts $6.7M loss and warns on cash runway - Stock Titan
Press Release: INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - Moomoo
INMB|INmune Bio Inc|Price:2.085|Chg%:+0.175 - TradingKey
INmune Bio Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
INmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.com UK
INmune Bio receives ~$4.6M in R&D rebates, cash proceeds exceed Q2 operating cash use - TradingView
INmune Bio (INMB.US) will release its earnings report after market close on August 6. - Moomoo
INmune Bio Inc.Common stock (INMB) Stock Price, News, Quote & History - financialcontent.com
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on ... - Caledonian Record
INmune Bio schedules Aug. 6 webcast on second-quarter results - Stock Titan
INmune Bio forms scientific advisory board for cell therapy By Investing.com - Investing.com Nigeria
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform - The Manila Times
INMB Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INMB|INmune Bio Inc|Price:1.745|Chg%:+0.125 - TradingKey
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
INMB|INmune Bio Inc|Price:1.620|Chg%:-0.100 - TradingKey
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio (INMB) Slips 2.2% as Stock Tests Support Near $1.60Rounding Top - po-news-eg.net
INmune Bio (INMB) Slides 6.5% as Selling Pressure Mounts, Tests Key Support at $1.63Dealer Positioning - dars.gov.et
Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway - Ad-hoc-news.de
INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus
INmune Bio And 2 Other Promising Penny Stocks To Consider - webull.com
INmune Bio Achieves Commercial-Ready Manufacturing Milestone for CORDStrom Platform Ahead of Planned Phase 3 Trial - Quiver Quantitative
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform - The Manila Times
INmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trial - Stock Titan
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio publishes preclinical study on brain injury link to Alzheimer’s - Investing.com Nigeria
INmune Bio Study Finds Soluble TNF Inhibition with XPro1595 Prevents TBI-Driven Amyloid Pathology in Alzheimer’s Model - Quiver Quantitative
In mice, XPro1595 prevented amyloid rise after brain injury - Stock Titan
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study - The Manila Times
INmune Bio Reports Positive Phase 2 XPro Data - t.co
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's disease at AAIC - marketscreener.com
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
INmune Bio reports imaging data from Alzheimer’s drug trial By Investing.com - Investing.com Nigeria
INmune Bio reports imaging data from Alzheimer’s drug trial - Investing.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lowdell Mark William | Chief Scientific Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
7,211 |
10,095 |
1,518,017 |
| Moss David J | Chief Executive Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
9,014 |
12,620 |
1,294,883 |
0.39%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):